Clinical data | |
---|---|
Trade names | Avelox, Vigamox, Moxiflox, others |
Other names | Moxifloxacine; BAY 12-8039 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a600002 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous, eye drops |
Drug class | Antibiotic (fluoroquinolone) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 86%[2] |
Protein binding | 47%[2] |
Metabolism | Glucuronide and sulfate conjugation; CYP450 system not involved[3] |
Elimination half-life | 12.1 hours[2] |
Excretion | Urine, feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.129.459 |
Chemical and physical data | |
Formula | C21H24FN3O4 |
Molar mass | 401.438 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Moxifloxacin is an antibiotic, used to treat bacterial infections,[4] including pneumonia, conjunctivitis, endocarditis, tuberculosis, and sinusitis.[4][5] It can be given by mouth, by injection into a vein, and as an eye drop.[5]
Common side effects include diarrhea, dizziness, and headache.[4] Severe side effects may include spontaneous tendon ruptures, nerve damage, and worsening of myasthenia gravis.[4] Safety of use in pregnancy and breastfeeding is unclear.[6] Moxifloxacin is in the fluoroquinolone family of medications.[4] It usually kills bacteria by blocking their ability to duplicate DNA.[4]
Moxifloxacin was patented in 1988 and approved for use in the United States in 1999.[7][8] It is on the World Health Organization's List of Essential Medicines.[9] In 2021, it was the 286th most commonly prescribed medication in the United States, with more than 700,000 prescriptions.[10][11]